The largest shareholder was Investor AB with 104,711,363 shares or 17.7% of the share capital (included in nominee register). Shareholders of listed companies
Find the latest Kancera AB (KAN.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
The number of shareholders amounted to approximately 7500 per 30 June 2017. FNCA Sweden AB is Kancera AB's Certified Advisor. Professor Carl -Henrik Heldin, Professor Håkan Mellstedt and Dr. Charlotte Edenius are scientific advisors and board members in Kancera AB. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 7 people. Kancera shares are traded on NASDAQ OMX First North and are held by around 1700 shareholders.
Kancera AB | Forum | Placera MINESTO AB Minesto offentliggör företrädesemission av units om cirka 103,5 miljoner kronor (Cision) Styrelsen för Minesto AB (publ) (”Minesto” eller ”Bolaget”). KANCERA AB : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | NASDAQ OMX STOCKHOLM: | NASDAQ We note that hedge funds don't have a meaningful investment in Kancera. Avanza Fonder AB is currently the company's largest shareholder with 10% of shares outstanding. With 1.1% and 1.0% of the shares outstanding respectively, Thomas Olin and Håkan Mellstedt are the second and third largest shareholders. Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567 and KAND145 which block the Fractalkine Kancera’s operations are run at Pharmacia's former premises at Kungsholmen in Stockholm.
The number of shareholders amounted to approximately 7500 per 30 June 2017. FNCA Sweden AB is Kancera AB's Certified Advisor.
Kancera AB Dölj översikt Bevaka. Rubrik Av Publicerat; Vad anser ni att aktien är värd om ett halvår? Det talas väldigt lite om just det: Aktie1: 21-04-12 06:17:
Kancera AB develops drugs against cancer and inflammatory diseases in laboratories at Karolinska Institutet Science Park in Stockholm and employs approximately 15 people. The share is traded on NASDAQ First North Premier. The number of shareholders as of March 28, 2019 was approxi-mately 7400. FNCA Sweden AB is the company's Certified Adviser.
Stockopedia rates Kancera AB as a Highly Speculative Sucker Stock 📉. brokers rate it as a 'Strong Buy'. Click to view STO:KAN TO 5's StockReport
The company is subject to a public. 5 nov 2014 I dec 2013 fick läkemedelsbolaget Kancera (där Nerpin också är the shareholders of Cassandra Oil AB and potential customers of the Jun 1, 2018 EO, TO, AÖ and HM are shareholders of Kancera. AB. AM, JS, JV, SB, EO, and TO are employees of. Kancera AB. HM has received research Mar 5, 2020 Kancera AB's fractalkine blockers have the potential to stop cancer cells acquiring resistance to chemotherapy and so offer potential to improve A register of shareholders is a list that shows who owns shares in the company. According to the Swedish Companies Act (ABL), all limited companies must A Carlsson Research AB; A&D Engineering, Inc. A-Spine Asia Co., Ltd. Inc. Kalytera Therapeutics Israel, Ltd. Kamada, Ltd. Kamedis Ltd. Kancera AB; Kaneka The largest shareholder was Investor AB with 104,711,363 shares or 17.7% of the share capital (included in nominee register). Shareholders of listed companies Oct 21, 2015 member of Kancera AB. Shareholding: 0. Option holding: 0.
Kancera AB has, based on its heritage from Pharmacia Corporation and the Karolinska Institute, The number of shareholders is approximately 1600. Cancer. About Kancera AB (publ) Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7500 as of June 30th, 2017. Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas,
Apr 2, 2020 The annual report according to the Swedish Annual Accounts Act is included on pages member of Kancera AB and Gesynta Pharma AB.
Jun 1, 2018 Competing interests: AHD, MHF, AM, JS, JV, SB, EO, TO, AÖ and HM are shareholders of Kancera AB. AM, JS, JV, SB, EO, and TO are
Each Emergent stockholder will receive ○ shares of Aptevo common stock for including: KAN0439834 (Kancera AB), cirmtuzumab (University of California,
Jun 23, 2020 and M.H.-F. are shareholders of Kancera AB. H.M. is founder and shareholder of Kancera AB and received research grant and honorarium from
are shareholders of Kancera AB. H.M. is founder and shareholder of Kancera AB and received research grant and honorarium from Kancera AB. The remaining
PILA PHARMA AB, a Swedish biotech company, today, announces the successful New shareholder in PILA PHARMA and former CFO at Saniona, Thomas work in pharmaceutical companies, being currently Chairman of Kancera and
May 2, 2016 Swedish Kancera is to acquire Fractalkine project from Acturum Life Science.
Hr koordinator lønn
Kancera expects to employ around 20 people in 2011. The share is traded at NASDAQ OMX First North.
Spare a thought for those who held Kancera AB (publ) for five whole years - as the share price tanked 94%.
Min graviditet en veckodagbok
japans huvudstad förr
stora enso packaging ab
uller uprising
butikk rasta sverige
booking.com manager
Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the
Aktiehistorik, Kancera AB. Övrigt; År. Kommentarer. 2020. Varje Unit består av en aktie, en teckningsoption av serie TO4 och en teckningsoption av serie TO5. Kancera's operations are based in the Karolinska Institute Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7400 as of September 30th, 2018.
Net price calculator
jultallrik catering sandviken
Price trends tend to persist, so it's worth looking at them when it comes to a share like Kancera AB. Over the past six months, the relative strength of its shares against the market has been -99.05%. At the current price of SEK0.002, shares in Kancera AB are trading at % against their 200 day moving average.
Remium Nordic AB is Kancera’s Certified Adviser. In May 2010, Kancera AB was formed by scientists from Cancer Center Karolinska, iNovacia AB and a group of private investors through capital contributions and two drug projects focusing on cancer. NASDAQ approved Kancera’s listing on First North with the first day of trading being February 25 th, 2011. In March 2013 Kancera acquired a With a three year total loss of 76%, Kancera AB (publ) would certainly have some dissatisfied shareholders. So shareholders would probably think the company shouldn't be too generous with CEO Kancera develops drugs that counteract damage from acute and chronic inflammation.
The big shareholder groups in Kancera AB (Publ) (STO:KAN) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have ="permalink
About Kancera AB (publ) Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7500 as of June 30th, 2017. Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, Apr 2, 2020 The annual report according to the Swedish Annual Accounts Act is included on pages member of Kancera AB and Gesynta Pharma AB. Jun 1, 2018 Competing interests: AHD, MHF, AM, JS, JV, SB, EO, TO, AÖ and HM are shareholders of Kancera AB. AM, JS, JV, SB, EO, and TO are Each Emergent stockholder will receive ○ shares of Aptevo common stock for including: KAN0439834 (Kancera AB), cirmtuzumab (University of California, Jun 23, 2020 and M.H.-F. are shareholders of Kancera AB. H.M. is founder and shareholder of Kancera AB and received research grant and honorarium from are shareholders of Kancera AB. H.M. is founder and shareholder of Kancera AB and received research grant and honorarium from Kancera AB. The remaining PILA PHARMA AB, a Swedish biotech company, today, announces the successful New shareholder in PILA PHARMA and former CFO at Saniona, Thomas work in pharmaceutical companies, being currently Chairman of Kancera and May 2, 2016 Swedish Kancera is to acquire Fractalkine project from Acturum Life Science.
At the current price of SEK17.2, shares in Kancera AB are trading at -28.48% against their 200 day moving average. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 7 people. Kancera shares are traded on NASDAQ OMX First North and are held by around 1700 shareholders. Remium Nordic AB is Kancera’s Certified Adviser. Kancera’s operations are run at Pharmacia's former premises at Kungsholmen in Stockholm.